Re: Quality-Adjusted Survival with First-Line Cabozantinib or Sunitinib for Advanced Renal Cell Carcinoma in the CABOSUN Randomized Clinical Trial (Alliance)

被引：0
|
作者：
Laguna, Pilar M.
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 205卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1819 / 1820
页数：3
相关论文
共 50 条
  • [1] Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)
    Chen, Ronald C.
    Choueiri, Toni K.
    Feuilly, Marion
    Meng, Jie
    Lister, Johanna
    Marteau, Florence
    Falchook, Aaron D.
    Morris, Michael J.
    George, Daniel J.
    Feldman, Darren R.
    CANCER, 2020, 126 (24) : 5311 - 5318
  • [2] Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib
    Aragon-Ching, Jeanny B.
    Madan, Ravi A.
    CANCER, 2020, 126 (24) : 5210 - 5212
  • [3] Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
    George, Daniel J.
    Hessel, Colin
    Halabi, Susan
    Michaelson, M. Dror
    Hahn, Olwen
    Walsh, Meghara
    Picus, Joel
    Small, Eric J.
    Dakhil, Shaker
    Feldman, Darren R.
    Mangeshkar, Milan
    Scheffold, Christian
    Morris, Michael J.
    Choueiri, Toni K.
    ONCOLOGIST, 2019, 24 (11): : 1497 - 1501
  • [4] Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 96 - 96
  • [5] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
    Vitale, Maria Giuseppa
    Nasso, Cecilia
    Oltrecolli, Marco
    Baldessari, Cinzia
    Fanelli, Martina
    Dominici, Massimo
    Sabbatini, Roberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
  • [6] Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?
    Buti, Sebastiano
    Bersanelli, Melissa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) : 1858 - +
  • [7] Clinically important difference in quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-A (IFN)
    Mallick, R.
    Hudes, G.
    Levy, D. E.
    VALUE IN HEALTH, 2007, 10 (06) : A342 - A342
  • [8] Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
    Zhou, Ai-Ping
    Bai, Yuxian
    Song, Yan
    Luo, Hong
    Ren, Xiu-Bao
    Wang, Xiuwen
    Shi, Benkang
    Fu, Cheng
    Cheng, Ying
    Liu, Jiyan
    Qin, Shukui
    Li, Jun
    Li, Hanzhong
    Bai, Xianzhong
    Ye, Dingwei
    Wang, Jinwan
    Ma, Jianhui
    ONCOLOGIST, 2019, 24 (08): : E702 - E708
  • [9] Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Bourlon, M. T.
    Zurawski, B.
    Oyervides Juarez, V. M.
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Barrios, C. H.
    Richardet, M.
    Pook, D.
    Tomita, Y.
    Escudier, B.
    Zhang, J.
    Simsek, B.
    Apolo, A. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1159 - S1159
  • [10] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
    Benjamin Duy Tran
    Jing Li
    Neang Ly
    Raffaella Faggioni
    Lorin Roskos
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189
12345